Viz’s technology has demonstrated decreased NIHSS, Discharge mRS, and 90 day mrs in patients triaged with Viz.*
*Fifi, et al. Impact of Viz LVO on Time-to-Treatment and Clinical Outcomes in Large Vessel Occlusion Stroke Patients Presenting to Primary Stroke Centers. 2020.
Connect multi-disciplinary care teams earlier, coordinate care, and improve outcomes for patients.
The Viz.ai webinar & podcast series features upcoming and on-demand peer to peer learning.
Intelligent Care Coordination enables faster care delivery and reduces the strain placed on providers.
Viz.ai continues to make a significant impact on stroke through the intelligent care platform in combination with Viz LVO, Viz CTP, and Viz ICH modules. The combination of Al powered alerts, a high fidelity mobile image viewer with pre-PACS timing and a HIPAA compliant communication tool, Viz LVO has powered the stroke workflow reducing Door to Treatment from 202 minutes to under 60, as supported by multiple publications.1-7
Four posters and one oral abstract presented at ISC22 focused on results with Viz. Highlights include new data from UCSD in the VISIION study7, where DTG times improved by 32% (41 min) in direct patients with LVO. The University of Ohio (Wexner) presented a poster further supporting the accuracy of ICH where 82 of 83 patients were detected.8 An oral abstract by the same institution further supported the sensitivity and specificity of Viz LVO in the real world.9
Two posters further validated the accuracy of Viz CTP. A poster by Atrium Health compared the Hypointensity Ratio (HIR) of Viz to Rapid and found the agreement in “Moderate to very good range” by Intraclass Correlation Coefficient (ICC) standards.10 Another poster abstract by University of Cincinnati highlighted “no difference in EVT eligibility using Viz or Rapid when both DEFUSE3/DAWN criteria were considered.”11
For more detail on the VISIION study, view the poster presentation by Morgan E Figurelle, DO, lead author of the poster abstract, in the video below or link to the poster abstract.
A well-attended Learning Studio on The Impact of AI on Stroke Care was hosted by Dr. Ameer Hassan from Valley Baptist in south Texas where he presented his Viz experience in a 13 hospital network. Dr. Hassan shares his published data in DIDO, DTG, patient outcomes and access to care.5,12,13
We’re excited to announce our latest clearance, Viz ANEURYSM. A first-of-its-kind population health tool that uses AI to automatically detect suspected cerebral aneurysms and standardize workflow across the health system. The combination of detection with an ability to schedule patients for neurovascular specialist follow-up is an important advancement for aneurysm patients to help improve outcomes.
Viz SDH was initially developed as a tool within Viz RECRUIT to assist with trials for SDH. Viz SDH is offered as an investigational device with the Medtronic EMBOLISE trial for the endovascular treatment of subdural hematomas. Investigational use only. Not for sale in the US.
The SDH algorithm has been submitted to FDA and is now 510(k) pending. Once approved, the software can be used outside of a trial. 510(k) Pending. Not for sale in the United States.
Partner hospitals of TeleSpecialists and Viz.ai will be able to integrate the Viz.ai platform into the TeleSpecialists telecare platform for a more seamless and integrated workflow experience. View the press release to learn more.
If you’re a stroke coordinator, you don’t want to miss the best practice discussion moderated by our very own Daniel D’Amour, MBA, RN, CEN, SCRN. In 10 minutes, Daniel shares nationwide examples of changes to workflow that have positively impacted time to treatment. He’s joined by Erin Cekovich, BSN, SCRN, ASC and Cesar Velasco, BSN, RN, SCRN, ASC from PennState Health.